Roche expands its digital health strategy

Global pharmaceutical company Roche has acquired a mobile diabetes platform to bolster its digital health services.

The company announced that it acquired mySugr to help expand its position in diabetes management.

The mySugr platform consists of apps and services that include diabetes coaching, therapy management, unlimited test-strips, automated data tracking and integration with a number of medical devices.

Roche intend for mySugr to be used as a focal point for its  integrated diabetes management strategy. Users of mySugr will still have access to the service’s functionality.

Roland Diggelmann, CEO Roche Diagnostics, said: “We are excited about this agreement, as we will be able to offer t better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life. Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”

Frank Westermann, CEO and Co-Founder of mySugr, said: “We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones. The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life.”



Reece Armstrong is a reporter for Digital Health Age. Coming from the North East of England, Reece has an MA in Media & Journalism and a BA in Popular & Contemporary Music from Newcastle University. Reach him on Twitter or email via: reece.armstrong@rapidnews.com


'Roche expands its digital health strategy' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2018 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions